Skip to main content
Top
Published in: Journal of Diabetes & Metabolic Disorders 2/2020

01-12-2020 | Respiratory Microbiota | Research article

Intestinal Microbiota Composition in Iranian Diabetic, Pre-diabetic and Healthy Individuals

Authors: Farahnaz Ghaemi, Abolfazl Fateh, Abbas Akhavan Sepahy, Mehrangiz Zangeneh, Mostafa Ghanei, Seyed Davar Siadat

Published in: Journal of Diabetes & Metabolic Disorders | Issue 2/2020

Login to get access

Abstract

Background

Type 2 diabetes, as the most prevalent metabolic disorder, is one of the leading causes of death worldwide. Recent studies showed a significant association between intestinal microbiota and type 2 diabetes. These studies have shared evidences that alteration in the composition of intestinal microbiota can disrupt the balance of the host homeostasis and lead to metabolic disorders such as type 2 diabetes. In the present study, we compared the intestinal microbiota composition in three groups of type 2 diabetes patients, pre-diabetic patients and healthy individuals of Iranian population.

Methods

After obtaining informed consent, stool samples were collected from 90 individuals of three studied groups. The DNA was extracted using column-based method. Intestinal microbiota composition was evaluated by quantitative real-time PCR using specific bacterial 16S rRNA primers. The difference of bacterial load was compared between three groups.

Results

The prevalence of Akkermansia muciniphila and Bifidobacteria species in healthy group was higher than type 2 diabetes group (P Value 0.006 and 0.001, respectively). In contrast, the load of Lactobacillus (P Value 0.044), Escherichia coli (P Value 0.005), and Bacteroides fragilis (P Value 0.017) in type 2 diabetes group, and the frequency of E. coli (P Value 0.001) and Bacteroides fragilis (P Value 0.004) in pre-diabetic group was significantly higher than healthy group. Moreover, the frequency of Faecalibacterium prausnitzii in healthy group was significantly higher compared to two other groups (P Value 0.005).

Conclusion

There is a correlation between intestinal microbiota composition and type 2 diabetes. Determination and restoration of this microbiota composition pattern may have a possible role in prevention and control of type 2 diabetes in a certain population.
Literature
1.
go back to reference Ho JT, Chan GC, Li JC. Systemic effects of gut microbiota and its relationship with disease and modulation. BMC Immunol. 2015;16:21.CrossRef Ho JT, Chan GC, Li JC. Systemic effects of gut microbiota and its relationship with disease and modulation. BMC Immunol. 2015;16:21.CrossRef
2.
go back to reference Scott KP, Gratz SW, Sheridan PO, Flint HJ, Duncan SH. The influence of diet on the gut microbiota. Pharmacol Res. 2013;69(1):52–60.CrossRef Scott KP, Gratz SW, Sheridan PO, Flint HJ, Duncan SH. The influence of diet on the gut microbiota. Pharmacol Res. 2013;69(1):52–60.CrossRef
3.
go back to reference Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M, et al. Human gut microbiome viewed across age and geography. Nature. 2012;486(7402):222–7.CrossRef Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M, et al. Human gut microbiome viewed across age and geography. Nature. 2012;486(7402):222–7.CrossRef
4.
go back to reference Hasan N, Yang H. Factors affecting the composition of the gut microbiota, and its modulation. PeerJ. 2019;7:e7502.CrossRef Hasan N, Yang H. Factors affecting the composition of the gut microbiota, and its modulation. PeerJ. 2019;7:e7502.CrossRef
5.
go back to reference Young VB. The intestinal microbiota in health and disease. Curr Opin Gastroenterol. 2012;28(1):63–9.CrossRef Young VB. The intestinal microbiota in health and disease. Curr Opin Gastroenterol. 2012;28(1):63–9.CrossRef
6.
go back to reference Boulange CL, Neves AL, Chilloux J, Nicholson JK, Dumas ME. Impact of the gut microbiota on inflammation, obesity, and metabolic disease. Genome Med. 2016;8(1):42.CrossRef Boulange CL, Neves AL, Chilloux J, Nicholson JK, Dumas ME. Impact of the gut microbiota on inflammation, obesity, and metabolic disease. Genome Med. 2016;8(1):42.CrossRef
7.
go back to reference Tang WH, Kitai T, Hazen SL. Gut Microbiota in Cardiovascular Health and Disease. Circ Res. 2017;120(7):1183–96.CrossRef Tang WH, Kitai T, Hazen SL. Gut Microbiota in Cardiovascular Health and Disease. Circ Res. 2017;120(7):1183–96.CrossRef
8.
go back to reference Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 2016;7(3):189–200.CrossRef Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 2016;7(3):189–200.CrossRef
9.
go back to reference d'Hennezel E, Abubucker S, Murphy LO, Cullen TW. Total Lipopolysaccharide from the Human Gut Microbiome Silences Toll-Like Receptor Signaling. mSystems. 2017;2(6). d'Hennezel E, Abubucker S, Murphy LO, Cullen TW. Total Lipopolysaccharide from the Human Gut Microbiome Silences Toll-Like Receptor Signaling. mSystems. 2017;2(6).
10.
go back to reference Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005;115(5):1111–9.CrossRef Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005;115(5):1111–9.CrossRef
11.
go back to reference Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860–7.CrossRef Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860–7.CrossRef
12.
go back to reference Kasubuchi M, Hasegawa S, Hiramatsu T, Ichimura A, Kimura I. Dietary gut microbial metabolites, short-chain fatty acids, and host metabolic regulation. Nutrients. 2015;7(4):2839–49.CrossRef Kasubuchi M, Hasegawa S, Hiramatsu T, Ichimura A, Kimura I. Dietary gut microbial metabolites, short-chain fatty acids, and host metabolic regulation. Nutrients. 2015;7(4):2839–49.CrossRef
13.
go back to reference Lin L, Zhang J. Role of intestinal microbiota and metabolites on gut homeostasis and human diseases. BMC Immunol. 2017;18(1):2.CrossRef Lin L, Zhang J. Role of intestinal microbiota and metabolites on gut homeostasis and human diseases. BMC Immunol. 2017;18(1):2.CrossRef
14.
go back to reference Pussinen PJ, Havulinna AS, Lehto M, Sundvall J, Salomaa V. Endotoxemia is associated with an increased risk of incident diabetes. Diabetes Care. 2011;34(2):392–7.CrossRef Pussinen PJ, Havulinna AS, Lehto M, Sundvall J, Salomaa V. Endotoxemia is associated with an increased risk of incident diabetes. Diabetes Care. 2011;34(2):392–7.CrossRef
15.
go back to reference Adeshirlarijaney A, Gewirtz AT. Considering gut microbiota in treatment of type 2 diabetes mellitus. Gut Microbes 2020:1–12. Adeshirlarijaney A, Gewirtz AT. Considering gut microbiota in treatment of type 2 diabetes mellitus. Gut Microbes 2020:1–12.
16.
go back to reference Baothman OA, Zamzami MA, Taher I, Abubaker J, Abu-Farha M. The role of Gut Microbiota in the development of obesity and Diabetes. Lipids Health Dis. 2016;15:108.CrossRef Baothman OA, Zamzami MA, Taher I, Abubaker J, Abu-Farha M. The role of Gut Microbiota in the development of obesity and Diabetes. Lipids Health Dis. 2016;15:108.CrossRef
17.
go back to reference Carvalho BM, Saad MJ. Influence of gut microbiota on subclinical inflammation and insulin resistance. Mediat Inflamm. 2013;2013:986734.CrossRef Carvalho BM, Saad MJ. Influence of gut microbiota on subclinical inflammation and insulin resistance. Mediat Inflamm. 2013;2013:986734.CrossRef
18.
go back to reference Cani PD, Osto M, Geurts L, Everard A. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes. 2012;3(4):279–88.CrossRef Cani PD, Osto M, Geurts L, Everard A. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes. 2012;3(4):279–88.CrossRef
19.
go back to reference Munoz-Garach A, Diaz-Perdigones C, Tinahones FJ. Gut microbiota and type 2 diabetes mellitus. Endocrinol Nutr. 2016;63(10):560–8.CrossRef Munoz-Garach A, Diaz-Perdigones C, Tinahones FJ. Gut microbiota and type 2 diabetes mellitus. Endocrinol Nutr. 2016;63(10):560–8.CrossRef
20.
go back to reference Li M, Gong J, Cottrill M, Yu H, de Lange C, Burton J, et al. Evaluation of QIAamp DNA Stool Mini Kit for ecological studies of gut microbiota. J Microbiol Methods. 2003;54(1):13–20.CrossRef Li M, Gong J, Cottrill M, Yu H, de Lange C, Burton J, et al. Evaluation of QIAamp DNA Stool Mini Kit for ecological studies of gut microbiota. J Microbiol Methods. 2003;54(1):13–20.CrossRef
21.
go back to reference D'Argenio V, Salvatore F. The role of the gut microbiome in the healthy adult status. Clin Chim Acta. 2015;451(Pt A):97–102.CrossRef D'Argenio V, Salvatore F. The role of the gut microbiome in the healthy adult status. Clin Chim Acta. 2015;451(Pt A):97–102.CrossRef
22.
go back to reference Sommer F, Backhed F. The gut microbiota--masters of host development and physiology. Nat Rev Microbiol. 2013;11(4):227–38.CrossRef Sommer F, Backhed F. The gut microbiota--masters of host development and physiology. Nat Rev Microbiol. 2013;11(4):227–38.CrossRef
23.
go back to reference Karlsson FH, Tremaroli V, Nookaew I, Bergstrom G, Behre CJ, Fagerberg B, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013;498(7452):99–103.CrossRef Karlsson FH, Tremaroli V, Nookaew I, Bergstrom G, Behre CJ, Fagerberg B, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013;498(7452):99–103.CrossRef
24.
go back to reference Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490(7418):55–60.CrossRef Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490(7418):55–60.CrossRef
25.
go back to reference Le KA, Li Y, Xu X, Yang W, Liu T, Zhao X, et al. Alterations in fecal Lactobacillus and Bifidobacterium species in type 2 diabetes patients in Southern China population. Front Physiol. 2012;3:496.PubMed Le KA, Li Y, Xu X, Yang W, Liu T, Zhao X, et al. Alterations in fecal Lactobacillus and Bifidobacterium species in type 2 diabetes patients in Southern China population. Front Physiol. 2012;3:496.PubMed
26.
go back to reference Wu X, Ma C, Han L, Nawaz M, Gao F, Zhang X, et al. Molecular characterisation of the faecal microbiota in patients with type 2 diabetes. Curr Microbiol. 2010;61(1):69–78.CrossRef Wu X, Ma C, Han L, Nawaz M, Gao F, Zhang X, et al. Molecular characterisation of the faecal microbiota in patients with type 2 diabetes. Curr Microbiol. 2010;61(1):69–78.CrossRef
27.
go back to reference Navab-Moghadam F, Sedighi M, Khamseh ME, Alaei-Shahmiri F, Talebi M, Razavi S, et al. The association of type 2 diabetes with gut microbiota composition. Microb Pathog. 2017;110:630–6.CrossRef Navab-Moghadam F, Sedighi M, Khamseh ME, Alaei-Shahmiri F, Talebi M, Razavi S, et al. The association of type 2 diabetes with gut microbiota composition. Microb Pathog. 2017;110:630–6.CrossRef
28.
go back to reference Sedighi M, Razavi S, Navab-Moghadam F, Khamseh ME, Alaei-Shahmiri F, Mehrtash A, et al. Comparison of gut microbiota in adult patients with type 2 diabetes and healthy individuals. Microb Pathog. 2017;111:362–9.CrossRef Sedighi M, Razavi S, Navab-Moghadam F, Khamseh ME, Alaei-Shahmiri F, Mehrtash A, et al. Comparison of gut microbiota in adult patients with type 2 diabetes and healthy individuals. Microb Pathog. 2017;111:362–9.CrossRef
29.
go back to reference Halawa MR, El-Salam MA, Mostafa BM, Sallout SS. The Gut Microbiome, Lactobacillus acidophilus; Relation with Type 2 Diabetes Mellitus. Curr Diabetes Rev. 2019;15(6):480–5.CrossRef Halawa MR, El-Salam MA, Mostafa BM, Sallout SS. The Gut Microbiome, Lactobacillus acidophilus; Relation with Type 2 Diabetes Mellitus. Curr Diabetes Rev. 2019;15(6):480–5.CrossRef
30.
go back to reference Ejtahed H-S, Hoseini-Tavassol Z, Khatami S, Zangeneh M, Behrouzi A, Ahmadi Badi S, et al. Main gut bacterial composition differs between patients with type 1 and type 2 diabetes and non-diabetic adults. Journal of Diabetes & Metabolic Disorders. 2020;19(1):265–71.CrossRef Ejtahed H-S, Hoseini-Tavassol Z, Khatami S, Zangeneh M, Behrouzi A, Ahmadi Badi S, et al. Main gut bacterial composition differs between patients with type 1 and type 2 diabetes and non-diabetic adults. Journal of Diabetes & Metabolic Disorders. 2020;19(1):265–71.CrossRef
31.
go back to reference Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science. 2011;334(6052):105–8.CrossRef Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science. 2011;334(6052):105–8.CrossRef
32.
go back to reference Remely M, Hippe B, Zanner J, Aumueller E, Brath H, Haslberger AG. Gut Microbiota of Obese, type 2 diabetes Individuals is Enriched in Faecalibacterium prausnitzii, Akkermansia muciniphila and Peptostreptococcus anaerobius after Weight Loss. Endocr Metab Immune Disord Drug Targets. 2016;16(2):99–106.CrossRef Remely M, Hippe B, Zanner J, Aumueller E, Brath H, Haslberger AG. Gut Microbiota of Obese, type 2 diabetes Individuals is Enriched in Faecalibacterium prausnitzii, Akkermansia muciniphila and Peptostreptococcus anaerobius after Weight Loss. Endocr Metab Immune Disord Drug Targets. 2016;16(2):99–106.CrossRef
Metadata
Title
Intestinal Microbiota Composition in Iranian Diabetic, Pre-diabetic and Healthy Individuals
Authors
Farahnaz Ghaemi
Abolfazl Fateh
Abbas Akhavan Sepahy
Mehrangiz Zangeneh
Mostafa Ghanei
Seyed Davar Siadat
Publication date
01-12-2020
Publisher
Springer International Publishing
Published in
Journal of Diabetes & Metabolic Disorders / Issue 2/2020
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1007/s40200-020-00625-x

Other articles of this Issue 2/2020

Journal of Diabetes & Metabolic Disorders 2/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.